BioNxt Solutions AI Stock Analysis
Want to see TSE:BNXT full AI Analyst Report?
BioNxt Solutions (BNXT) AI Stock Analysis
BioNxt Solutions
(CNQX:BNXT)
The company faces an existential financial crisis with no revenue, insolvency, and accelerating cash burn. The stock is in a persistent downtrend across all timeframes, and negative earnings render valuation metrics useless. The overall score reflects a severely distressed, high-risk investment with no observable strengths.
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 32.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 37.04K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 0.23
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 25
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
BioNxt Solutions Business Overview & Revenue Model
Company Description
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, incl...
BioNxt Solutions Financial Statement Overview
Summary
Financial performance is critically distressed. Revenue has collapsed to near zero, gross profit is deeply negative, and the company is insolvent with negative equity. Cash burn is accelerating with no internal generation, indicating an existential crisis.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -11.26K | 0 | 26.98K | 372.25K | 297.44K | 286.50K |
| Gross Profit | -18.45K | -10.90K | 26.98K | 372.25K | 195.62K | 199.48K |
| EBITDA | -8.72M | -6.04M | -4.32M | -6.48M | -11.51M | -19.19M |
| Net Income | -10.55M | -7.03M | -5.31M | -7.72M | -12.38M | -20.64M |
Balance Sheet | ||||||
| Total Assets | 586.34K | 591.68K | 569.36K | 1.27M | 1.61M | 9.73M |
| Cash, Cash Equivalents and Short-Term Investments | 199.41K | 55.26K | 32.35K | 363.65K | 136.20K | 1.35M |
| Total Debt | 6.16M | 5.95M | 4.28M | 4.89M | 4.37M | 5.46M |
| Total Liabilities | 7.19M | 9.96M | 8.43M | 6.55M | 5.74M | 8.06M |
| Stockholders Equity | -6.61M | -9.37M | -7.86M | -5.28M | -4.13M | 1.67M |
Cash Flow | ||||||
| Free Cash Flow | -3.53M | -5.20M | -3.03M | -5.37M | -6.23M | -12.61M |
| Operating Cash Flow | -3.53M | -5.20M | -3.03M | -5.17M | -6.23M | -12.16M |
| Investing Cash Flow | 93.66K | 87.43K | 56.21K | 100.84K | -3,858 | -5.31M |
| Financing Cash Flow | 3.17M | 5.13M | 2.64M | 5.29M | 5.02M | 16.23M |
BioNxt Solutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.31, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.88 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.
BioNxt Solutions Peers Comparison
Overall Rating
TSE:LABS55Neutral
TSE:AVCN48Neutral
TSE:INNO45Neutral
TSE:ATLE42Neutral
TSE:BNXT37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | CAD 23.49M | -9.23 | -7.66% | ― | -9.31% | 66.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | CAD 11.42M | -3.86 | -65.40% | ― | -3.32% | -34.15% | |
| 45Neutral | CAD 8.05M | -6.01 | -19.37% | ― | -19.20% | 42.54% | |
| 42Neutral | CAD 37.30M | -0.76 | -2099.75% | ― | -96.13% | 88.13% | |
| 37Underperform | CAD 32.66M | -2.91 | 142.79% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BNXT | Bionxt Solutions Inc | 0.24 | -0.45 | -65.22% | |
| TSE:ATLE | Willow Biosciences | 0.08 | -0.07 | -46.67% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.06 | -0.01 | -7.69% | |
| TSE:AVCN | Avicanna Inc | 0.09 | -0.15 | -64.58% | |
| TSE:INNO | Innocan Pharma Corporation | 1.79 | -11.00 | -86.00% |
BioNxt Solutions Corporate Events
BioNxt Extends Convertible Debentures and Issues 16.9 Million Warrants
NeutralBioNxt Solutions Inc., a bioscience company focused on advanced drug delivery platforms and diagnostic technologies for autoimmune, neurological and longevity-related conditions, operates R&D facilities in North America and Europe while targeting Eur...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
